

REMARKS

Claims 1-14 are active in the present application. The claims are amended to remove multiple dependencies. Claims 11-14 find support in Claims 1-10 and the specification. No new matter is added. An action on the merits and allowance the claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon  
Attorney of Record  
Registration No. 24,618

Daniel J. Pereira, Ph.D.  
Registration No. 45,518



**22850**

(703) 413-3000  
Fax #: (703) 413-2220  
NFO:DJP\cct

I:\user\DJPER\20472US-pr.wpd

20070620 14:00:00

**Marked-Up Copy**

Serial No: \_\_\_\_\_

Amendment Filed on: \_\_\_\_\_

IN THE CLAIMS

Please amend the claims as follows:

--3. (Amended) Use according to claim 1 [or 2], wherein the bacterial strain is a *Lactobacillus plantarum* strain.

4. (Amended) Use according to [any of claims 1 to 3] claim 1 of *Lactobacillus plantarum* 299v, deposition number DSM 9843.

5. (Amended) Use according to [any of claims 1-4] claim 1 for the reduction of IL-6 in blood.

6. (Amended) Use according to [any of claims 1-4] claim 1 for the reduction of the level of reactive oxygen species in blood.

7. (Amended) Use according to [any of claims 1-4] claim 1 for the reduction of the adhesion of monocytes to endothelial cells.

8. (Amended) Use according to [any of claims 1-4] claim 1 for the manufacture of a medicament for the prophylaxis and/or treatment of chronic inflammatory diseases.--